化学
吡唑
三氟甲基
生物利用度
部分
立体化学
化学合成
效力
体内
选择性
药代动力学
甲酰胺
体外
药理学
生物化学
有机化学
烷基
催化作用
生物技术
生物
医学
作者
Mimi L. C. Quan,Patrick Y. S. Lam,Qi Han,Donald J. P. Pinto,Ming Y. He,Renhua Li,Christopher D. Ellis,Charles G. Clark,Christopher A. Teleha,Jung‐Hui Sun,Richard Alexander,Steve Bai,Joseph M. Luettgen,Robert M. Knabb,Pancras C. Wong,Ruth R. Wexler
摘要
Modification of a series of pyrazole factor Xa inhibitors to incorporate an aminobenzisoxazole as the P(1) ligand resulted in compounds with improved selectivity for factor Xa relative to trypsin and plasma kallikrein. Further optimization of the P(4) moiety led to compounds with enhanced permeability and reduced protein binding. The SAR and pharmacokinetic profile of this series of compounds is described herein. These efforts culminated in 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide (11d), a potent, selective, and orally bioavailable inhibitor of factor Xa. On the basis of its excellent in vitro potency and selectivity profile, high free fraction in human plasma, good oral bioavailability, and in vivo efficacy in antithrombotic models, the HCl salt of this compound was selected for clinical development as razaxaban (DPC 906, BMS-561389).
科研通智能强力驱动
Strongly Powered by AbleSci AI